Interpretation and optimization of the dissolution specifications for a modified release product with an in vivo-in vitro correlation (IVIVC)

被引:16
|
作者
Hayes, S
Dunne, A [1 ]
Smart, T
Davis, J
机构
[1] Univ Coll Dublin, Dept Stat, Dublin 4, Ireland
[2] Pfizer Global Res & Dev, Sandwich, Kent, England
关键词
dissolution specifications; in vivo-in uitro correlation (IVIVC); bioequivalence; optimization;
D O I
10.1002/jps.10552
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This article considers the in vivo significance attached to in vitro dissolution testing. Almost invariably, the in vitro dissolution test is interpreted in terms of bioequivalence. The literature that describes methods for setting in vitro dissolution specifications is reviewed. The most common interpretation of these specifications is a deterministic one, that is, those batches passing the dissolution specifications would be bioequivalent with the reference if tested in vivo and those failing the dissolution specifications would not be bioequivalent if tested in vivo. Due to random variation, the deterministic interpretation is not appropriate. Instead, we need to consider the conditional probability that a batch that has passed the in vitro dissolution test would demonstrate bioequivalence if tested in vivo, and that a batch known to have failed the in vitro dissolution test would demonstrate bioinequivalence if tested in vivo. One way to estimate these probabilities is by means of a simulated experiment in which the production and testing (in vivo and in vitro) of a large number of batches is computer simulated. Such a simulation can only be performed if the relationship between the in vitro dissolution characteristics and the in vivo performance of the product has been modeled. These models are generally referred to as in vivo-in vitro correlations (IVIVC). The results of one such experiment are described. The above-mentioned conditional probabilities are shown to depend on the choice of dissolution specifications. This result leads to the notion of optimal dissolution specifications. However, both of the conditional probabilities cannot be maximized simultaneously. The probability of making a correct decision on the basis of the in vitro dissolution test is introduced as a possible optimality criterion. This probability is a linear combination of the two conditional probabilities of interest. Using this criterion, the optimal dissolution specifications can be found by searching over the multidimensional space defined by the half width of each interval used in the specifications to find the combination that maximizes this probability. This process is demonstrated using the Nelder-Mead search routine. The choice of dissolution specifications has profound implications for the routine production of the product because if the specifications were very narrow the probability of a batch passing would be low, resulting in a low hit rate. The same computer program used to perform the simulation experiment can be used to estimate the hit rate. Furthermore, it can be used to explore the magnitude of changes required in the parameters describing the test product (particularly variability) to increase a low hit rate to an acceptable level. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:571 / 581
页数:11
相关论文
共 50 条
  • [21] Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen
    Camara-Martinez, I
    Blechar, J. A.
    Ruiz-Picazo, A.
    Garcia-Arieta, A.
    Calandria, C.
    Merino-Sanjuan, V
    Langguth, P.
    Gonzalez-Alvarez, M.
    Bermejo, M.
    Al-Gousous, J.
    Gonzalez-Alvarez, I
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 614
  • [22] In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers
    Balan, G
    Timmins, P
    Greene, DS
    Marathe, PH
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 90 (08) : 1176 - 1185
  • [23] In vivo-in vitro correlation for amoxicillin trihydrate 1000 mg dispersible tablet
    Ostrowski, Michal
    Wilkowska, Ewa
    Baczek, Tomasz
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2009, 35 (08) : 981 - 985
  • [24] Quantitative Assessment of the in vivo Dissolution Rate to Establish a Modified IVIVC for Isosorbide Mononitrate Tablets
    Zhang, Guoqing
    Zhang, Li
    Tan, Yuexiang
    Wang, Lei
    Cheng, Zeneng
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 112 (06) : 1705 - 1714
  • [25] Setting dissolution specifications for modified-release dosage forms
    Piscitelli, DA
    Young, D
    IN VITRO-IN VIVO CORRELATIONS, 1997, 423 : 159 - 166
  • [26] Application of the correlation of in vitro dissolution behavior and in vivo plasma concentration profile (IVIVC) for soft-gel capsules -: a pointless pursuit?
    Nishimura, Hidekatsu
    Hayashi, Chlaki
    Aiba, Tetsuya
    Okamoto, Ichiro
    Miyamoto, Yuji
    Nakade, Susumu
    Takeda, Kazuhisa
    Kurosaki, Yuji
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (11) : 2221 - 2225
  • [27] In Vitro-In Vivo and In Vivo-In Vivo Correlations of TAF Release From a Novel Subdermal Implant
    Moss, John
    Gunawardana, Manjula
    Remedios-Chan, Mariana
    Sanchez, Debbie
    Webster, Simon
    Baum, Marc
    Weinberger, Dana
    Chatterji, Udayan
    Kuo, Joseph
    Gallay, Philippe
    Motamedi, Massoud
    Vincent, Kathleen
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 359 - 359
  • [28] In Vitro-In Vivo Correlation (IVIVC) Population Modeling for the In Silico Bioequivalence of a Long-Acting Release Formulation of Progesterone
    Tosca, Elena M.
    Rocchetti, Maurizio
    Perez, Elena
    Nieto, Conchi
    Bettica, Paolo
    Moscoso del Prado, Jaime
    Magni, Paolo
    De Nicolao, Giuseppe
    PHARMACEUTICS, 2021, 13 (02) : 1 - 26
  • [29] Towards in vitro in vivo correlation for modified release subcutaneously administered insulins
    Bock, Frederik
    Lin, Eva
    Larsen, Claus
    Jensen, Henrik
    Huus, Kasper
    Larsen, Susan Weng
    Ostergaard, Jesper
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 145
  • [30] In Vitro-In Vivo Correlation of Modified Release Dosage Form of Lamotrigine
    Shah, Hiten J.
    Subbaiah, Gunta
    Patel, Dasharath M.
    Patel, Chhagan N.
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2009, 30 (09) : 524 - 531